[-] Show simple item record

dc.contributor.authorGlendenning, Charleseng
dc.contributor.authorKaufmann, Leeeng
dc.date.issued2007eng
dc.description.abstractThere is no clearly superior oral agent for glycemic control in patients with type 2 diabetes. (Strength of Recommendation [SOR]: C) Metformin (Glucophage) has shown additional benefit when compared with other treatments (including insulin) for diabetes-related outcomes and all-cause mortality and should be considered the agent of choice for initial monotherapy, particularly in obese patients. (SOR: A)eng
dc.identifier.urihttp://hdl.handle.net/10355/3983eng
dc.languageEnglisheng
dc.publisherFamily Physicians Inquiries Networkeng
dc.relation.ispartofcollectionClinical Inquiries, 2007 (MU)eng
dc.relation.ispartofcommunityUniversity of Missouri-Columbia. School of Medicine. Department of Family and Community Medicine. Family Physicians Inquiries Networkeng
dc.relation.ispartofseriesAmerican family physician, 75, no. 07 (April 2007)eng
dc.rightsOpenAccess.eng
dc.rights.licenseThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 License.eng
dc.subjectA1C reductioneng
dc.subjectalpha-glucosidase inhibitorseng
dc.subjecthypoglycemiaeng
dc.subjectinsulin resistanceeng
dc.subject.lcshNon-insulin-dependent diabetes -- Treatmenteng
dc.subject.lcshHyperglycemia -- Treatmenteng
dc.subject.lcshBlood sugar monitoringeng
dc.titleGlycemic Control in Patients with Type 2 Diabeteseng
dc.typeArticleeng


Files in this item

[PDF]

This item appears in the following Collection(s)

[-] Show simple item record